GHRP-6: The Original GH-Releasing Peptide That Started It All
GHRP-6 is the first GH-releasing hexapeptide and ghrelin-receptor agonist — strong acute GH evidence, robust hunger effect, but largely superseded by cleaner analogues.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13The original GH-releasing hexapeptide and ghrelin-receptor agonist — the template for the class. Acute GH release and GHRH synergy are well-supported in humans, but the appetite and regenerative claims are mostly animal, it was never approved, and the field moved on. Strong (often unwanted) appetite spike; WADA-prohibited.
The founding GHSR-1a agonist; dual hypothalamic/pituitary action well mapped.
Broad animal data for appetite and organ-protection signals.
Multiple human studies of acute GH release and GHRH synergy.
Reliable acute GH provoker; appetite effect human-inferred, regenerative claims preclinical; no proven physique/clinical outcome.
Acute human exposure characterised; chronic-use safety unknown.
Never developed into a drug; the field moved to cleaner/oral analogues.
Confident on acute GH; downstream outcomes unproven.
Unapproved; WADA-prohibited; grey-market. In ACTIVE FDA Category 2 under the 503B interim policy (added 29 September 2023) — a compounding restriction, not an approval or endorsement.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
The original GH-releasing hexapeptide. Acute GH release and GHRH synergy are well-supported in humans, but the appetite and regenerative claims are mostly animal, and it was never developed into a drug.
Safety snapshot
Acute human exposure is characterised; chronic-use safety is unknown. It causes a strong (often unwanted) appetite spike, raises cortisol/prolactin, and the GH response desensitises with continuous use.
Regulatory & legality
Unapproved; WADA-prohibited; grey-market. The FDA lists "Growth hormone releasing peptide-6 (GHRP-6)" in the ACTIVE Category 2 table under the 503B interim policy, added 29 September 2023 — substances identified as potentially presenting significant safety risks in compounding. That is a compounding restriction, not an approval, a licence or an endorsement, and not a finding that every route or formulation is unsafe.
Where claims can exceed the evidence
Acute GH release is real, but downstream physique or clinical outcomes are unproven; the field moved on to cleaner analogues.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
GHRP-6 (growth hormone-releasing peptide-6) is, in a real sense, where the whole modern peptide-secretagogue story begins. It was the first GH-releasing hexapeptide studied extensively in humans, and it became the template from which the entire class — GHRP-2, hexarelin, and the orally active MK-677/ibutamoren — was later derived [2]. If you have ever read about ghrelin mimetics, you are reading about GHRP-6's descendants.
The evidence picture is unusually clear-cut for a grey-market peptide. There is strong, genuinely human evidence that GHRP-6 acutely releases growth hormone, and its mechanism is well understood at the cellular level [1][5][6]. What is not well established is everything downstream of that: the appetite and body-composition claims rest mostly on animal work, and the newer therapeutic uses (cardiac, kidney, wound healing) are almost entirely preclinical. GHRP-6 itself was never developed into an approved drug — the field moved on to orally active analogues, leaving GHRP-6 as a research chemical rather than a medicine.
This is an educational summary for informed readers, not medical advice or an endorsement of use.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
CJC-1295 With DAC: The GHRH Analog That Made It to Human Trials
An evidence-first look at CJC-1295 with DAC: real human PK/PD data, how albumin-binding extends its half-life to days, and why development was halted.
CJC-1295 Without DAC (Mod GRF 1-29): What the Evidence Actually Shows
A plain-English, evidence-first look at CJC-1295 without DAC: what it is, why its half-life is short, what the research does and does not show, and the real risks.
GHRP-2 (Pralmorelin): What the Evidence Actually Shows
GHRP-2 reliably triggers a growth hormone pulse and ramps up hunger, but the physique and longevity claims rest on weak, mostly acute data.
Hexarelin: The Old-School GH Peptide with a Heart-Focused Twist
A clear, evidence-first look at hexarelin: a potent 1990s growth hormone peptide with intriguing but animal-only cardiac claims and real desensitisation issues.